Department of Microbiology, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA
Department of Microbiology, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA.
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01919-18. Print 2019 Feb.
We performed bedaquiline broth microdilution susceptibility testing using Clinical and Laboratory Standards Institute (CLSI) guidelines on 104 nonduplicate isolates of complex [ subsp. (76); subsp. (10); subsp. (2); and subsp. - subsp. hybrid, i.e., subsp. by gene and subsp. by (41) gene (16)]. All isolates from patients not known to have been on bedaquiline prior had MIC values of ≤0.25 μg/ml. The bedaquiline MIC value for all 76 isolates of subsp. and 16 isolates of subsp. - subsp. hybrid was 0.06 μg/ml. The MIC and MIC values for 10 isolates of subsp. were 0.12 μg/ml. Only two isolates of subsp. were tested with bedaquiline MICs of 0.06 μg/ml. Our study suggests that oral bedaquiline may have potential use in the treatment of disease caused by the complex. Combination therapy with other agents (imipenem, cefoxitin, amikacin, and/or tigecycline) is recommended.
我们按照临床和实验室标准协会(CLSI)的指南,对 104 株非重复的 复合亚种(76);亚种(10);亚种(2);亚种-亚种杂种,即通过基因亚种和通过(41)基因亚种(16)进行了 bedaquiline 肉汤微量稀释药敏试验。所有来自未经 bedaquiline 治疗的患者的分离株的 MIC 值均≤0.25μg/ml。亚种的 76 株分离株和亚种-亚种杂种的 16 株分离株的 bedaquiline MIC 值均为 0.06μg/ml。亚种的 10 株分离株的 MIC 和 MIC 值为 0.12μg/ml。仅对亚种的 2 株分离株进行了 bedaquiline MIC 值为 0.06μg/ml 的检测。我们的研究表明,口服 bedaquiline 可能有潜力用于治疗由 复合亚种引起的疾病。建议与其他药物(亚胺培南、头孢西丁、阿米卡星和/或替加环素)联合治疗。